New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...
On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...
Medtronic said its rollout represents the largest-ever commercial launch of a brain-computer interface technology, with more than 40,000 patients worldwide already implanted with Percept ...
Medtronic has received CE marks under the European Union’s Medical Device Regulation (EU MDR) for the BrainSense adaptive deep brain stimulation (aDBS) system and electrode identifier (EI) for ...
Please provide your email address to receive an email when new articles are posted on . The adaptive deep brain stimulation technology is the first of its kind to address symptoms of Parkinson’s ...
For the one million people diagnosed with Parkinson's disease in the United States 1, Medtronic plc (NYSE: MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...
Medtronic has won FDA approval for a device that can help with therapy for those suffering from Parkinson’s Disease. The Dublin-based company’s BrainSense Adaptive deep brain stimulation (aDBS) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results